A team led by UF researchers Elias Sayour and Christiano Marconi discovered that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting an immunotherapy treatment for advanced forms of lung cancer or melanoma lived significantly longer than those who didn’t get the vaccine.
UF startup iOncologi, Inc. announced that USPTO has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.
UF researchers suggest that prediction models used by decision makers in attempting to control the spread of COVID-19 were incomplete, showing the need for more accurate forecasting.
UF researcher Frederick Southwick discusses the increased prevalence of respiratory viruses—influenza, COVID-19, and RSV—during the winter in Florida and provides tips on how to avoid them.
UF startup LPRC conducted a study to examine how theft and violence have evolved since before COVID-19. The study revealed a significant increase in both the average number of shoplifting incidents and the dollars lost due to shoplifting.
Researchers at the University of Florida have discovered the combination of Lactoferrin, a protein found in cow and human milk, and diphenhydramine, an antihistamine used for allergy symptoms, increased resilience of mice towards the virus that causes COVID-19.
UF researchers have discovered a combination of two over-the-counter compounds that may significantly improve the recovery of patients infected with COVID-19. Studies in mice have been successful, with the health of test subjects improving significantly or ending in full recovery.
College of Medicine researcher Dr. David Ostrov wrote this opinion piece for The Hill after his discovery of a potential therapy or preventative for COVID became public knowledge:
“Got milk? Cure COVID” was a meme that started circulating after one of our discoveries from the University of Florida went public. It playfully highlighted a major medical milestone: We had found a combination of two over-the-counter products that could inhibit 99 percent of SARS-CoV-2 replication in human lung cells, and one of them was milk-based.
Neobiosis, A UF Accelerate resident client, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”).
Going beyond pregnancy and COVID-19, the world could someday soon come to rely on at-home tests for many diseases thanks in part to AI-fueled improvements.
